Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL4155190 | 0.88 | PTGS2 (0.40) | BRD4WEE1JAK2PTGS2 | |
| Propionic Acid SCHEMBL4155344 | 0.84 | FASN (0.42) | F7PTGS2 | |
| Propionic Acid SCHEMBL4165833 | 0.84 | PAK1 (0.40) | BRD4WEE1 | |
| Propionic Acid SCHEMBL4162600 | 0.81 | PARP1 (0.38) | PTGS2 | |
| Propionic Acid SCHEMBL4162918 | 0.80 | BRAF (0.46) | — | |
| Butyric Acid SCHEMBL4153848 | 0.79 | FASN (0.41) | F7PTGS2 | |
| Propionic Acid SCHEMBL4155193 | 0.78 | RXFP1 (0.41) | — | |
| SCHEMBL4157978 | 0.78 | HPGD (0.39) | BRD4WEE1F7 | |
| Propionic Acid SCHEMBL4153840 | 0.78 | PIM1 (0.44) | — | |
| SCHEMBL3241482 | 0.78 | WEE1 (0.39) | BRD4WEE1PHLPP2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | BRD4 545/4885WEE1 563/4885PHLPP2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.